INNOGEN-B (02591) plans to invest HKD 50 million for on-market repurchase of H shares.

07:35 26/08/2026

Silver Noble Pharmaceuticals-B (02591) announced that from August 26, 2026, until the date of the next annual general meeting of shareholders, it intends to exercise its power under the buyback authorization in accordance with the special resolution passed by shareholders at the annual general meeting held on June 29, 2026, to repurchase H shares through on-market transactions on the Main Board of the Stock Exchange, with a total amount of approximately HKD 50 million (planned H shares buyback).

INNOGEN-B (02591) has announced that from August 26, 2026, until the date of the next annual general meeting of shareholders, it intends to exercise its power under the repurchase authorization based on the special resolution passed by shareholders at the annual general meeting held on June 29, 2026, to repurchase H-shares on the main board of the Stock Exchange through on-market transactions, with a proposed total amount of approximately HKD 50 million (proposed H-share repurchase).

Brokerage Morning Meeting Highlights | Positive Outlook on Investments in the Power Industry Chain

DEEPZERO (02723) has signed a strategic cooperation memorandum of understanding with Deloitte China.

GENFLEET-B(02595): GFH375 (an oral KRAS G12D inhibitor) has entered a Phase II study for first-line treatment of non-small cell lung cancer, which will explore multiple treatment regimens including monotherapy, combination with EGFR monoclonal antibodies, or chemotherapy.

Brokerage Morning Meeting Highlights | Positive Outlook on Investments in the Power Industry Chain

DEEPZERO (02723) has signed a strategic cooperation memorandum of understanding with Deloitte China.